191 related articles for article (PubMed ID: 29721755)
1. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
[TBL] [Abstract][Full Text] [Related]
2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract][Full Text] [Related]
4. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Muñoz M; González-Ortega A; Coveñas R
Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
[TBL] [Abstract][Full Text] [Related]
5. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.
Ge C; Huang H; Huang F; Yang T; Zhang T; Wu H; Zhou H; Chen Q; Shi Y; Sun Y; Liu L; Wang X; Pearson RB; Cao Y; Kang J; Fu C
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19635-19645. PubMed ID: 31488714
[TBL] [Abstract][Full Text] [Related]
6. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
[TBL] [Abstract][Full Text] [Related]
7. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
Nizam E; Köksoy S; Erin N
Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138.
Muñoz M; Rosso M; Coveñas R; Montero I; González-Moles MA; Robles MJ
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2775-81. PubMed ID: 17525212
[TBL] [Abstract][Full Text] [Related]
9. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
10. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C
Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608
[TBL] [Abstract][Full Text] [Related]
11. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
12. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
13. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
[TBL] [Abstract][Full Text] [Related]
14. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
15. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines.
Muñoz M; Pérez A; Rosso M; Zamarriego C; Rosso R
Melanoma Res; 2004 Jun; 14(3):183-8. PubMed ID: 15179186
[TBL] [Abstract][Full Text] [Related]
17. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
20. CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
Ding H; Vincelette ND; McGehee CD; Kohorst MA; Koh BD; Venkatachalam A; Meng XW; Schneider PA; Flatten KS; Peterson KL; Correia C; Lee SH; Patnaik M; Webster JA; Ghiaur G; Smith BD; Karp JE; Pratz KW; Li H; Karnitz LM; Kaufmann SH
Cancer Res; 2021 May; 81(10):2666-2678. PubMed ID: 33414171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
